Malaria vaccine study canceled before it began
NCT ID NCT07208760
First seen Nov 01, 2025 · Last updated May 18, 2026 · Updated 31 times
Summary
This study was designed to see if giving a monoclonal antibody (L9LS) before the R21/Matrix-M malaria vaccine changes how well the vaccine works. It planned to enroll healthy adults and infants in Mali. However, the study was withdrawn before any participants were enrolled, so no results are available.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALARIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Sotuba Malaria Research and Training Center (MRTC)
Sotouba, Mali
Conditions
Explore the condition pages connected to this study.